RIP3 is widely involved in physiological and pathological processes, and new RIP3 inhibitors can be used as probes to explore the roles of RIP3 enzymatic activity in addition to their potential applications in RIP3 hyperactivation-associated pathological settings such as inflammatory bowel disease, chronic obstructive pulmonary disease, multiple sclerosis, and toxic epidermal necrolysis. This evidence concerns the gene RIPK3 and toxic epidermal necrolysis.